Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma

(2015) E. Massarelli et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck

(2014) Nabil F. Saba et al.   CANCER

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

(2014) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of nutritional interventions on nutritional status, quality of life and mortality in patients with head and neck cancer receiving (chemo)radiotherapy: a systematic review

(2013) Jacqueline A.E. Langius et al.   CLINICAL NUTRITION

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

(2013) Julie E. Bauman et al.   ORAL ONCOLOGY

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

An integrated map of genetic variation from 1,092 human genomes

(2012)   NATURE

Immune Suppression in Head and Neck Cancers: A Review

(2011) Anaëlle Duray et al.   Clinical & Developmental Immunology

Prevalence of Secondary Lymphedema in Patients With Head and Neck Cancer

(2011) Jie Deng et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2011) N. Stransky et al.   SCIENCE

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

(2008) D L Wheeler et al.   ONCOGENE